August 10, 2020 - Page 17 of 23

NASDAQ Companies - August 10, 2020

Paratek Pharmaceuticals Announces Second Quarter 2020 Total Revenue of $9.3 Million including NUZYRA® (omadacycline) Net Revenue of $8.1 Million

— Paratek Raises Full Year 2020 Revenue Guidance; Total Revenue guidance expected to be Between $78 and $83 Million Driven by Strong NUZYRA Net Revenue— [...]

NASDAQ Companies - August 10, 2020

Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress

Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Clinical Activity Against Genetically-Defined TumorsTargeted Combination Strategy Underpins Initiation of […]

NASDAQ Companies - August 10, 2020

Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update

NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development […]

NASDAQ Companies - August 10, 2020

Aemetis to Review Second Quarter Financial Results on August 13, 2020

CUPERTINO, CA, Aug. 10, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Aemetis, Inc. (NASDAQ: AMTX) announced that the company will […]

NASDAQ Companies - August 10, 2020

Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases

MALVERN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and […]

NASDAQ Companies - August 10, 2020

Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis

Finalizing preparations for pharmacokinetic (PK) clinical trials of AQST-108First planned PK clinical trial expected to begin during the third quarter […]

TSX Venture News - August 10, 2020

Paratek Pharmaceuticals Announces Second Quarter 2020 Total Revenue of $9.3 Million including NUZYRA® (omadacycline) Net Revenue of $8.1 Million

Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress

Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Aemetis to Review Second Quarter Financial Results on August 13, 2020

Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases

Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis

Serengeti Provides Kwanika Update – Drilling to Begin

FTI Consulting Leads Who’s Who Legal Restructuring & Insolvency Advisers List

Front Yard Residential Corporation Reports Second Quarter 2020 Results

Platinex Announces Private Placement Financing with a Lead Order from Palisades Goldcorp